2023-04-14 ブラウン大学
研究では、マウスの脳腫瘍の治療に成功し、人間の臨床試験への応用が期待されている。この成分は、複数の治療メカニズムに対して同時に働くため、グリオブラストーマの治療に有効と考えられている。
<関連情報>
- https://www.brown.edu/news/2023-04-14/glioblastoma-drug
- https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(23)00129-5
6′-ブロモインジルビンアセトキシムのナノ粒子製剤「PPRX-1701」がデリバリーを改善し、前臨床のGBMモデルで有効性を示す PPRX-1701, a nanoparticle formulation of 6′-bromoindirubin acetoxime, improves delivery and shows efficacy in preclinical GBM models
Mykola Zdioruk,Jorge-Luis Jimenez-Macias,Michal Oskar Nowicki,Katherine E. Manz,Kurt D. Pennell,Marilin S. Koch,Tomer Finkelberg,Bin Wu,Paul Boucher,Yuji Takeda,Weiyi Li,Raziye Piranlioglu,Alexander L. Ling,E. Antonio Chiocca,Sean E. Lawler
Cell Reports Medicine Published:April 14, 2023
DOI:https://doi.org/10.1016/j.xcrm.2023.101019
Highlights
•PPRX-1701 is a deliverable formulation of 6-bromoindirubin-3′-acetoxime (BiA)
•Inhibits IDO1 expression and increases CD8 T cell infiltration in GBM mouse models
•Data support investigation of this approach for future potential translation
Summary
Derivatives of the Chinese traditional medicine indirubin have shown potential for the treatment of cancer through a range of mechanisms. This study investigates the impact of 6′-bromoindirubin-3′-acetoxime (BiA) on immunosuppressive mechanisms in glioblastoma (GBM) and evaluates the efficacy of a BiA nanoparticle formulation, PPRX-1701, in immunocompetent mouse GBM models. Transcriptomic studies reveal that BiA downregulates immune-related genes, including indoleamine 2,3-dioxygenase 1 (IDO1), a critical enzyme in the tryptophan-kynurenine-aryl hydrocarbon receptor (Trp-Kyn-AhR) immunosuppressive pathway in tumor cells. BiA blocks interferon-γ (IFNγ)-induced IDO1 protein expression in vitro and enhances T cell-mediated tumor cell killing in GBM stem-like cell co-culture models. PPRX-1701 reaches intracranial murine GBM and significantly improves survival in immunocompetent GBM models in vivo. Our results indicate that BiA improves survival in murine GBM models via effects on important immunotherapeutic targets in GBM and that it can be delivered efficiently via PPRX-1701, a nanoparticle injectable formulation of BiA.
